These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 8637514)

  • 1. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.
    Fisher CJ; Agosti JM; Opal SM; Lowry SF; Balk RA; Sadoff JC; Abraham E; Schein RM; Benjamin E
    N Engl J Med; 1996 Jun; 334(26):1697-702. PubMed ID: 8637514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.
    Moreland LW; Baumgartner SW; Schiff MH; Tindall EA; Fleischmann RM; Weaver AL; Ettlinger RE; Cohen S; Koopman WJ; Mohler K; Widmer MB; Blosch CM
    N Engl J Med; 1997 Jul; 337(3):141-7. PubMed ID: 9219699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study.
    Mease PJ; Wei N; Fudman EJ; Kivitz AJ; Schechtman J; Trapp RG; Hobbs KF; Greenwald M; Hou A; Bookbinder SA; Graham GE; Wiesenhutter CW; Willis L; Ruderman EM; Forstot JZ; Maricic MJ; Dao KH; Pritchard CH; Fiske DN; Burch FX; Prupas HM; Anklesaria P; Heald AE
    J Rheumatol; 2010 Apr; 37(4):692-703. PubMed ID: 20032102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
    Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
    N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble TNFR II/IgG1 Fc fusion protein treatment in the LPS-mediated septic shock of rats.
    Guo Z; Wang S; Jiao Q; Xu M; Xu Z
    Biomed Pharmacother; 2009 Aug; 63(7):537-42. PubMed ID: 18848768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study.
    Mease PJ; Hobbs K; Chalmers A; El-Gabalawy H; Bookman A; Keystone E; Furst DE; Anklesaria P; Heald AE
    Ann Rheum Dis; 2009 Aug; 68(8):1247-54. PubMed ID: 18678578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
    Weinblatt ME; Kremer JM; Bankhurst AD; Bulpitt KJ; Fleischmann RM; Fox RI; Jackson CG; Lange M; Burge DJ
    N Engl J Med; 1999 Jan; 340(4):253-9. PubMed ID: 9920948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritis.
    Furst DE; Weisman M; Paulus HE; Bulpitt K; Weinblatt M; Polisson R; Zaug M; Kneer J; Van der Auwera P; Stevens RM
    J Rheumatol; 2003 Oct; 30(10):2123-6. PubMed ID: 14528504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor receptor: Fc fusion protein in septic shock.
    Whiteley MS
    N Engl J Med; 1996 Nov; 335(21):1607-8; author reply 1608-9. PubMed ID: 8927111
    [No Abstract]   [Full Text] [Related]  

  • 10. Tumor necrosis factor receptor: Fc fusion protein in septic shock.
    Glauser MP; Cohen J
    N Engl J Med; 1996 Nov; 335(21):1608; author reply 1608-9. PubMed ID: 8927112
    [No Abstract]   [Full Text] [Related]  

  • 11. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
    Rau R; Sander O; van Riel P; van de Putte L; Hasler F; Zaug M; Kneer J; van der Auwera P; Stevens RM;
    J Rheumatol; 2003 Apr; 30(4):680-90. PubMed ID: 12672184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-inflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis.
    Butty VL; Roux-Lombard P; Garbino J; Dayer JM; Ricou B;
    Eur Cytokine Netw; 2003; 14(1):15-9. PubMed ID: 12799209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
    Targan SR; Hanauer SB; van Deventer SJ; Mayer L; Present DH; Braakman T; DeWoody KL; Schaible TF; Rutgeerts PJ
    N Engl J Med; 1997 Oct; 337(15):1029-35. PubMed ID: 9321530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
    Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
    JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant tumor necrosis factor receptor p75 fusion protein (TNFR:Fc) alters endotoxin-induced activation of the kinin, fibrinolytic, and coagulation systems in normal humans.
    DeLa Cadena RA; Majluf-Cruz A; Stadnicki A; Tropea M; Reda D; Agosti JM; Colman RW; Suffredini AF
    Thromb Haemost; 1998 Jul; 80(1):114-8. PubMed ID: 9684796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.
    Abraham E; Laterre PF; Garbino J; Pingleton S; Butler T; Dugernier T; Margolis B; Kudsk K; Zimmerli W; Anderson P; Reynaert M; Lew D; Lesslauer W; Passe S; Cooper P; Burdeska A; Modi M; Leighton A; Salgo M; Van der Auwera P;
    Crit Care Med; 2001 Mar; 29(3):503-10. PubMed ID: 11373411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
    Abraham E; Wunderink R; Silverman H; Perl TM; Nasraway S; Levy H; Bone R; Wenzel RP; Balk R; Allred R
    JAMA; 1995 Mar 22-29; 273(12):934-41. PubMed ID: 7884952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group.
    Jatoi A; Dakhil SR; Nguyen PL; Sloan JA; Kugler JW; Rowland KM; Soori GS; Wender DB; Fitch TR; Novotny PJ; Loprinzi CL
    Cancer; 2007 Sep; 110(6):1396-403. PubMed ID: 17674351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration.
    Suffredini AF; Reda D; Banks SM; Tropea M; Agosti JM; Miller R
    J Immunol; 1995 Nov; 155(10):5038-45. PubMed ID: 7594512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists.
    Mohler KM; Torrance DS; Smith CA; Goodwin RG; Stremler KE; Fung VP; Madani H; Widmer MB
    J Immunol; 1993 Aug; 151(3):1548-61. PubMed ID: 8393046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.